| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 28 | 2025 | 567 | 5.950 |
Why?
|
| Neoplasm Recurrence, Local | 22 | 2024 | 312 | 3.690 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 19 | 2025 | 375 | 3.490 |
Why?
|
| Uterine Cervical Neoplasms | 15 | 2025 | 285 | 2.600 |
Why?
|
| Endometrial Neoplasms | 14 | 2024 | 187 | 2.100 |
Why?
|
| Immunoconjugates | 3 | 2023 | 17 | 1.640 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2022 | 31 | 1.530 |
Why?
|
| Paclitaxel | 11 | 2021 | 184 | 1.500 |
Why?
|
| Female | 64 | 2025 | 14663 | 1.320 |
Why?
|
| Adenocarcinoma | 8 | 2018 | 288 | 1.260 |
Why?
|
| Genital Neoplasms, Female | 5 | 2022 | 61 | 1.160 |
Why?
|
| Antineoplastic Agents | 6 | 2024 | 660 | 1.090 |
Why?
|
| Hysterectomy | 9 | 2020 | 85 | 1.070 |
Why?
|
| Middle Aged | 43 | 2025 | 6914 | 1.070 |
Why?
|
| Adult | 38 | 2025 | 7507 | 1.020 |
Why?
|
| Aged | 34 | 2025 | 5231 | 0.990 |
Why?
|
| Humans | 67 | 2025 | 27169 | 0.990 |
Why?
|
| Yttrium Radioisotopes | 1 | 2025 | 4 | 0.960 |
Why?
|
| Aged, 80 and over | 19 | 2025 | 1944 | 0.880 |
Why?
|
| Carcinoma, Endometrioid | 4 | 2020 | 39 | 0.850 |
Why?
|
| Bevacizumab | 10 | 2023 | 93 | 0.850 |
Why?
|
| Salvage Therapy | 3 | 2018 | 32 | 0.720 |
Why?
|
| Indazoles | 4 | 2024 | 16 | 0.720 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2018 | 155 | 0.710 |
Why?
|
| Sulfonamides | 2 | 2018 | 70 | 0.710 |
Why?
|
| Triazoles | 3 | 2024 | 15 | 0.700 |
Why?
|
| Hydrazines | 3 | 2024 | 13 | 0.700 |
Why?
|
| Pyrimidines | 2 | 2018 | 121 | 0.690 |
Why?
|
| Retrospective Studies | 21 | 2020 | 2457 | 0.690 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2024 | 99 | 0.670 |
Why?
|
| Chemoradiotherapy | 5 | 2025 | 44 | 0.630 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 38 | 0.600 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 66 | 0.570 |
Why?
|
| Lymph Nodes | 3 | 2018 | 98 | 0.550 |
Why?
|
| Vulvar Neoplasms | 3 | 2016 | 25 | 0.540 |
Why?
|
| Sarcoma | 1 | 2016 | 28 | 0.510 |
Why?
|
| Neoplasm Staging | 15 | 2025 | 462 | 0.500 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2025 | 151 | 0.500 |
Why?
|
| Uterine Neoplasms | 1 | 2016 | 70 | 0.490 |
Why?
|
| Cisplatin | 8 | 2025 | 175 | 0.480 |
Why?
|
| Survival Rate | 12 | 2021 | 411 | 0.460 |
Why?
|
| Pyridines | 2 | 2025 | 102 | 0.450 |
Why?
|
| Brachytherapy | 5 | 2025 | 50 | 0.410 |
Why?
|
| Piperidines | 2 | 2024 | 45 | 0.410 |
Why?
|
| CA-125 Antigen | 3 | 2008 | 19 | 0.400 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2025 | 133 | 0.400 |
Why?
|
| Maintenance Chemotherapy | 4 | 2024 | 15 | 0.380 |
Why?
|
| Lymphatic Metastasis | 5 | 2020 | 119 | 0.370 |
Why?
|
| Lymph Node Excision | 5 | 2020 | 96 | 0.340 |
Why?
|
| Disease-Free Survival | 8 | 2020 | 225 | 0.330 |
Why?
|
| Follow-Up Studies | 7 | 2024 | 989 | 0.320 |
Why?
|
| Neoplasms | 3 | 2024 | 768 | 0.320 |
Why?
|
| Chemoradiotherapy, Adjuvant | 3 | 2020 | 12 | 0.320 |
Why?
|
| Clinical Trials as Topic | 4 | 2019 | 206 | 0.310 |
Why?
|
| Prognosis | 7 | 2020 | 763 | 0.300 |
Why?
|
| Maximum Tolerated Dose | 2 | 2025 | 31 | 0.300 |
Why?
|
| Biological Availability | 2 | 2024 | 43 | 0.290 |
Why?
|
| Incidental Findings | 2 | 2018 | 13 | 0.280 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2021 | 104 | 0.270 |
Why?
|
| Anastomosis, Surgical | 1 | 2006 | 37 | 0.260 |
Why?
|
| Platinum | 2 | 2023 | 17 | 0.250 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2017 | 67 | 0.250 |
Why?
|
| Double-Blind Method | 3 | 2024 | 405 | 0.240 |
Why?
|
| Vaginal Neoplasms | 1 | 2025 | 12 | 0.240 |
Why?
|
| CD47 Antigen | 1 | 2025 | 4 | 0.240 |
Why?
|
| CD40 Antigens | 1 | 2025 | 14 | 0.240 |
Why?
|
| Cadherins | 1 | 2025 | 24 | 0.240 |
Why?
|
| Robotics | 3 | 2010 | 42 | 0.240 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2025 | 36 | 0.230 |
Why?
|
| Radiopharmaceuticals | 1 | 2025 | 69 | 0.230 |
Why?
|
| Viral Vaccines | 1 | 2023 | 12 | 0.220 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2020 | 109 | 0.220 |
Why?
|
| Fallopian Tube Neoplasms | 2 | 2017 | 49 | 0.210 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2024 | 33 | 0.210 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 150 | 0.210 |
Why?
|
| Treatment Outcome | 6 | 2021 | 2286 | 0.200 |
Why?
|
| Carboplatin | 5 | 2021 | 107 | 0.190 |
Why?
|
| Chronic Disease | 1 | 2022 | 264 | 0.190 |
Why?
|
| Taxoids | 3 | 2013 | 36 | 0.190 |
Why?
|
| Risk Factors | 5 | 2020 | 2038 | 0.180 |
Why?
|
| Electrocardiography | 1 | 2022 | 391 | 0.180 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 24 | 0.180 |
Why?
|
| Withholding Treatment | 1 | 2020 | 20 | 0.170 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2010 | 31 | 0.170 |
Why?
|
| Phthalazines | 1 | 2019 | 22 | 0.160 |
Why?
|
| Drug Approval | 1 | 2019 | 9 | 0.160 |
Why?
|
| Angiopoietin-2 | 1 | 2019 | 10 | 0.160 |
Why?
|
| Angiopoietin-1 | 1 | 2019 | 8 | 0.160 |
Why?
|
| Piperazines | 1 | 2019 | 45 | 0.160 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2019 | 58 | 0.160 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 43 | 0.160 |
Why?
|
| Hypoalbuminemia | 1 | 2018 | 3 | 0.160 |
Why?
|
| Texas | 2 | 2016 | 134 | 0.150 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2018 | 12 | 0.150 |
Why?
|
| Fistula | 1 | 2018 | 17 | 0.150 |
Why?
|
| Radiosurgery | 1 | 2019 | 82 | 0.150 |
Why?
|
| Placebos | 1 | 2018 | 46 | 0.150 |
Why?
|
| Quality of Life | 2 | 2020 | 468 | 0.150 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 144 | 0.150 |
Why?
|
| Oncolytic Virotherapy | 1 | 2017 | 12 | 0.140 |
Why?
|
| Male | 3 | 2025 | 13043 | 0.140 |
Why?
|
| Colostomy | 2 | 2008 | 4 | 0.140 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2017 | 3 | 0.140 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2017 | 6 | 0.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2017 | 53 | 0.140 |
Why?
|
| Mutation | 1 | 2021 | 820 | 0.140 |
Why?
|
| Carcinoma | 1 | 2017 | 71 | 0.140 |
Why?
|
| Peritoneal Neoplasms | 1 | 2017 | 76 | 0.130 |
Why?
|
| Prosthesis Implantation | 1 | 2016 | 26 | 0.130 |
Why?
|
| Transportation of Patients | 1 | 2016 | 28 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 365 | 0.130 |
Why?
|
| Gestational Trophoblastic Disease | 1 | 2015 | 6 | 0.120 |
Why?
|
| Thiosemicarbazones | 2 | 2025 | 5 | 0.120 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2024 | 19 | 0.120 |
Why?
|
| Prospective Studies | 4 | 2023 | 1221 | 0.120 |
Why?
|
| Gonadal Dysgenesis, 46,XY | 1 | 2014 | 2 | 0.120 |
Why?
|
| Biomarkers, Tumor | 3 | 2020 | 377 | 0.110 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2014 | 15 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2014 | 64 | 0.110 |
Why?
|
| Attitude of Health Personnel | 2 | 2017 | 139 | 0.110 |
Why?
|
| Patient Selection | 1 | 2014 | 143 | 0.110 |
Why?
|
| Rectum | 2 | 2019 | 50 | 0.110 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 291 | 0.100 |
Why?
|
| United States | 1 | 2019 | 2063 | 0.100 |
Why?
|
| Conization | 1 | 2011 | 11 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2012 | 278 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 300 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2020 | 864 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 318 | 0.090 |
Why?
|
| Endometrium | 2 | 2022 | 38 | 0.090 |
Why?
|
| Platinum Compounds | 1 | 2009 | 13 | 0.080 |
Why?
|
| Outpatients | 1 | 2009 | 44 | 0.080 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2008 | 16 | 0.080 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 24 | 0.080 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 47 | 0.080 |
Why?
|
| Surgical Stomas | 1 | 2008 | 6 | 0.080 |
Why?
|
| Ulcer | 2 | 2019 | 5 | 0.070 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2008 | 70 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2008 | 63 | 0.070 |
Why?
|
| Colonic Diseases | 1 | 2008 | 10 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 262 | 0.070 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2007 | 33 | 0.070 |
Why?
|
| Topotecan | 2 | 2020 | 12 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 189 | 0.070 |
Why?
|
| Obesity, Morbid | 1 | 2007 | 50 | 0.070 |
Why?
|
| Colon, Sigmoid | 1 | 2006 | 1 | 0.070 |
Why?
|
| Ileostomy | 1 | 2006 | 6 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 342 | 0.060 |
Why?
|
| Thiadiazines | 1 | 2025 | 1 | 0.060 |
Why?
|
| Rectovaginal Fistula | 2 | 2019 | 4 | 0.060 |
Why?
|
| Gynecology | 2 | 2017 | 56 | 0.060 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2025 | 4 | 0.060 |
Why?
|
| B7-H1 Antigen | 1 | 2025 | 35 | 0.060 |
Why?
|
| Young Adult | 4 | 2015 | 2633 | 0.060 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2025 | 35 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 43 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2008 | 281 | 0.060 |
Why?
|
| Medical Oncology | 2 | 2017 | 87 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2024 | 166 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2019 | 191 | 0.060 |
Why?
|
| Therapeutic Equivalency | 1 | 2024 | 4 | 0.060 |
Why?
|
| Tablets | 1 | 2024 | 6 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2024 | 94 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2025 | 229 | 0.060 |
Why?
|
| Cross-Over Studies | 1 | 2024 | 132 | 0.050 |
Why?
|
| Fasting | 1 | 2024 | 80 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2024 | 589 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 217 | 0.050 |
Why?
|
| NEDD8 Protein | 1 | 2022 | 6 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 158 | 0.050 |
Why?
|
| Cervix Uteri | 1 | 2022 | 63 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2022 | 247 | 0.050 |
Why?
|
| Indoles | 1 | 2022 | 98 | 0.050 |
Why?
|
| Heart | 1 | 2022 | 221 | 0.050 |
Why?
|
| Epothilones | 1 | 2021 | 5 | 0.050 |
Why?
|
| Genes, p53 | 1 | 2021 | 14 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 23 | 0.050 |
Why?
|
| Sirolimus | 1 | 2021 | 69 | 0.040 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2019 | 2 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2019 | 15 | 0.040 |
Why?
|
| Rectal Diseases | 1 | 2019 | 10 | 0.040 |
Why?
|
| Safety | 1 | 2019 | 32 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 86 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 104 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 218 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2019 | 108 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 58 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 129 | 0.040 |
Why?
|
| Uterine Diseases | 1 | 2018 | 2 | 0.040 |
Why?
|
| Uterine Hemorrhage | 1 | 2018 | 9 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 510 | 0.040 |
Why?
|
| Endometrial Hyperplasia | 1 | 2018 | 6 | 0.040 |
Why?
|
| Palliative Care | 2 | 2009 | 79 | 0.040 |
Why?
|
| Reoviridae | 1 | 2017 | 2 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 2017 | 2 | 0.040 |
Why?
|
| Oncolytic Viruses | 1 | 2017 | 7 | 0.040 |
Why?
|
| Neutropenia | 1 | 2017 | 36 | 0.040 |
Why?
|
| Stretchers | 1 | 2016 | 1 | 0.030 |
Why?
|
| Lacerations | 1 | 2016 | 7 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 2017 | 87 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2016 | 58 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 52 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 102 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2015 | 26 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 160 | 0.030 |
Why?
|
| Adolescent | 2 | 2014 | 2997 | 0.030 |
Why?
|
| Urban Population | 1 | 2015 | 72 | 0.030 |
Why?
|
| Adnexa Uteri | 1 | 2014 | 2 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2014 | 29 | 0.030 |
Why?
|
| Poverty | 1 | 2015 | 82 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 726 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2013 | 39 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 934 | 0.030 |
Why?
|
| Polyglutamic Acid | 1 | 2012 | 3 | 0.020 |
Why?
|
| Second-Look Surgery | 1 | 2012 | 4 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 598 | 0.020 |
Why?
|
| Laparotomy | 1 | 2012 | 29 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 298 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 458 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 656 | 0.020 |
Why?
|
| Pregnancy | 1 | 2015 | 1154 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 17 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 72 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2010 | 32 | 0.020 |
Why?
|
| Pelvis | 1 | 2010 | 37 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2010 | 43 | 0.020 |
Why?
|
| Bartholin's Glands | 1 | 2009 | 1 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2009 | 11 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2009 | 34 | 0.020 |
Why?
|
| Microdissection | 1 | 2009 | 14 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2009 | 33 | 0.020 |
Why?
|
| Sarcoidosis | 1 | 2009 | 38 | 0.020 |
Why?
|
| Aorta | 1 | 2010 | 123 | 0.020 |
Why?
|
| Rupture, Spontaneous | 1 | 2009 | 10 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 455 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2008 | 26 | 0.020 |
Why?
|
| Alleles | 1 | 2009 | 345 | 0.020 |
Why?
|
| Prolapse | 1 | 2008 | 3 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 190 | 0.020 |
Why?
|
| Phenotype | 1 | 2010 | 668 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 2009 | 137 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2009 | 143 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2008 | 707 | 0.020 |
Why?
|
| Animals | 1 | 2019 | 10093 | 0.020 |
Why?
|